New antibiotic combo targets Drug-Resistant pneumonia
NCT ID NCT07492771
First seen Mar 28, 2026 · Last updated May 24, 2026 · Updated 5 times
Summary
This early-stage study tests a new drug called MP101, given alongside standard antibiotics, for adults with a severe lung infection caused by Pseudomonas aeruginosa bacteria. The main goal is to check if MP101 is safe and tolerable in 18 participants. Researchers will also measure how the drug moves in the body and how well it fights the bacteria.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PNEUMONIA - BACTERIAL are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Severance Hospital
Seoul, Seodaemun-gu, 03722, South Korea
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.